Pediatric brain tumor companies specialize in the development of treatments and therapies specifically designed for children with brain tumors. These companies play a crucial role in advancing pediatric oncology by researching and providing targeted therapies, chemotherapy agents, and supportive care for young patients diagnosed with brain tumors. Their commitment is to improve outcomes and minimize long-term effects for pediatric brain tumor survivors.
Novartis Received FDA approval for KISQALI (tafmidis meglumine) for the treatment of Desmoid Tumor, a rare cancer affecting both adults and children. Ongoing clinical trials of CAR-T cell therapy for medulloblastoma, a high-grade pediatric brain tumor.
AbbVie Launched their Venclexta (venetoclax) in combination with Rituximab for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), which can affect the brain in some cases Investing in research on targeted therapies for diffuse intrinsic pontine gliomas (DIPG), an aggressive pediatric brain tumor with limited treatment options.
Bluebird bio Received FDA approval for their gene therapy, Skysona (betibeglogene autotemcel), for the treatment of cerebral adrenoleukodystrophy (CALD), a rare pediatric brain disorder. Developing other gene therapy candidates for different types of pediatric brain tumors.
Orphazyme A/S Received FDA approval for arimoclomol for the treatment of Niemann-Pick disease type C, a rare neurodegenerative disorder that affects children and adults. Partnering with research institutions to explore its potential use in other pediatric brain disorders.
BeiGene, Received EMA approval for their Bruton's tyrosine kinase (BTK) inhibitor, Brukinsa (zanubrutinib), for the treatment of mantle cell lymphoma in pediatric patients.Ongoing clinical trials of Brukinsa for other types of pediatric B-cell malignancies, including some types of brain tumors.
Pediatric Brain Tumor Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)